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Abstract
The genetic diversity among human immunodeficiency virus (HIV) subtypes as well as the 
variability of viral sequences found in HIV-infected individuals presents a number of difficult 
obstacles for the development of universally effective HIV treatment and prevention methods. 
Here, we present a brief summary of recent developments in the analysis of viral genetics and 
human genomics to provide insight into future methods for HIV treatment and prevention. Recent 
studies have mined viral sequences found in newly infected individuals to identify common 
features of all transmitted viruses that could provide potential targets for HIV vaccine 
development. Analysis of human immunogenetics has identified specific alleles associated with 
reduced virus loads in HIV-infected individuals providing valuable information that may influence 
individual responses to treatment and prevention methods. Increased sensitivity of antiretroviral 
drug resistance testing has improved the detection of hidden drug resistant virus but also 
highlighted the potential for drug resistant viruses to reduce the effectiveness of clinical treatment 
regimens. The rapidly expanding amount of data generated by studies of viral genetics and human 
immunogenetics will provide valuable information to guide the design of new strategies to 
improve clinical treatment and enhance HIV vaccine development.
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Introduction
The pandemic of human immunodeficiency virus (HIV) infection continues to pose an 
enormously difficult public health challenge for a multitude of reasons. One of the most 
daunting aspects of the HIV epidemic is the extremely high level of genetic diversity among 
the 13 recognized global subtypes and at least 51 circulating recombinant forms [1]. The 
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degree of global diversity observed originates with the error-prone nature of the viral 
replication machinery and the ability of the viral genome to incorporate multiple nucleotide 
substitutions which, within infected individuals, results in a population of closely related, 
but genetically distinct variants termed quasispecies. Evolving HIV genetic diversity 
presents numerous obstacles for both the human immune response as well as the 
implementation of antiviral therapies, vaccines and microbicides. Recent studies utilizing 
new sequencing technologies and genomics tools have begun to reveal a vast amount of data 
regarding the genetics of both HIV and the human immune system. In this review, we will 
present a brief summary of recent studies examining HIV genetics and human genomics as 
well as how this body of knowledge will impact the development and implementation of 
future effective methods to both treat and prevent HIV infection.
Genetic Analysis of Transmitted Variants
Although the HIV global epidemic is characterized by an extraordinarily high level of viral 
genetic diversity, the viral quasispecies initially found in most individuals early in infection 
tends to be remarkably homogenous. Recent studies have focused on sampling sequences of 
the viral env gene from the viral quasispecies within HIV-infected individuals. The viral env 
gene encodes the highly variable viral surface glycoprotein (Env) required for entry into 
HIV target cells. Several studies based on recently infected individuals have established that 
in 60–90% of cases, depending on the population studied, HIV infection is apparently 
established by a single viral variant [2]. In multiple variant infections, only 2–5 variants can 
be found, although higher infection multiplicities have not been ruled out because sampling 
for many tissue compartments is not readily available. Infection with multiple variants has 
been observed to occur more frequently when the barrier of the host mucosal surface is 
compromised or bypassed, as with sexually transmitted infections, anal intercourse or 
intravenous drug users [3]. Additionally, infection with multiple variants has been linked to 
certain markers of faster disease progression [4]. Therefore, methods aimed at reducing the 
likelihood of infection with multiple variants, such as treatment of sexually transmitted 
infections in HIV-uninfected persons, will likely slow disease progression in those 
individuals who become HIV-infected.
Advances in bioinformatics analysis have enabled the compilation and comparison of viral 
sequences collected from a large number of newly infected individuals to identify common 
sequences and phenotypes that may be shared in HIV transmission. A recent study by 
Gnanakaran et al. [5] examined over 7,000 env sequences obtained from 275 samples 
collected during acute or chronic phases of HIV infection to search for signature genetic 
patterns specifically associated with acute infection. This analysis yielded 25 promising 
signatures, including the absence of a specific sequence known to facilitate viral escape from 
antibodies and several signatures that may be essential to proper expression and/or 
processing of the Env glycoprotein. Asmal et al. [6] extended this finding by demonstrating 
that sequences associated with acute infection indeed produce higher levels of Env and 
increased incorporation of Env into virions in vitro. Together these studies highlight the 
potential utility of mining large data sets of viral sequences from acute and chronic HIV 
infection for genetic patterns uniquely related to HIV transmission before specific 
hypotheses are further tested in experimental systems. Thus, genetic analysis of viral 
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sequences has begun to identify specific properties of all HIV transmitted variants that may 
be targeted in future vaccine and microbicide methods to prevent sexual transmission of 
HIV.
Evaluation of viral sequences in samples collected during clinical trials of HIV prevention 
strategies also afford the opportunity to examine breakthrough infections in treatment and 
control arms to identify characteristics of viral variants that manage to establish infection in 
the context of a specific intervention. The STEP trial, a double-blinded, phase 2b study of 
vaccine efficacy, attempted to induce immune responses against 3 HIV proteins, but the trial 
lacked efficacy in preventing infection [7]. Retrospectively, Rolland et al. [8] obtained and 
compared near full-length viral genomes from 68 HIV-infected individuals from both the 
vaccine and placebo arms of the STEP trial. Not surprisingly, breakthrough infections in the 
vaccine recipients were initiated by viruses with sequences divergent from the vaccine. 
Importantly, sequence differences between viruses establishing infection in vaccine and 
placebo recipients were almost exclusively restricted to the 3 viral proteins that comprised 
the vaccine. Thus, while this analysis highlights the challenges facing HIV vaccine 
development, the application of viral genetic analysis to breakthrough infections in clinical 
trials is being used to hone previously tested prevention methods in order to maximize 
efficacy. Taken together, novel strategies of analyzing HIV sequences are beginning to yield 
promising opportunities to develop new, and improve upon current, HIV prevention 
methods.
Insights from Analyses of Host Genomics
HIV diversity and its continuing evolution in human populations are dictated in part by host 
factors, including those that mediate innate and adaptive immune responses to HIV infection 
[9]. Comprehensive data from deep sequencing of the entire HIV genome [10] coupled with 
genome-wide search for host genetic factors important to HIV acquisition and control [11] 
are expected to facilitate a fine dissection of molecular mechanisms underlying the battle 
between HIV and host genomes.
To date, immunogenetics as a prominent frontier in AIDS research has already made 
important contributions to (i) identification of HIV-resistance factors (e.g. null CCR5 
alleles), (ii) the understanding of effective and durable immune control of HIV infection in 
elite or viremic controllers [12], (iii) mapping of viral epitopes for vaccine design, and (iv) 
evaluation of vaccine efficacy. Although human genomes have been scanned for patient 
populations with informative, HIV-related phenotypes [13, 14], several recent studies now 
offer new evidence that productive and transformative research may need to focus on 
systematic analysis of highly polymorphic human leukocyte antigen (HLA) molecules and 
killer cell immunoglobulin-like receptor (KIR) genes. Continued study of the complex virus/
host interaction will inform development and implementation of treatment and prevention 
regimens.
For example, 2 recent studies have demonstrated that individuals infected with HIV subtypes 
B and C have relatively low viral load when they carry HLA-DRB1*13:03, an infrequent 
allele that might have been missed by earlier studies for lack of statistical power [15, 16]. 
Haaland et al. Page 3













Favorable HLA class II alleles are likely to target epitopes in HIV Gag instead of Env [16], 
which is consistent with the well-established notion that immune recognition of conserved 
epitopes in HIV Gag may be a common mechanism for effective immune control, as 
immune escape mutations in Gag typically lead to reduced viral fitness. In the AIDS vaccine 
trial (RV144) in Thailand, lack of neutralizing antibody (nAb) response was associated with 
HLA-DRB1 variants *11 and *16:02 [17]; vaccine recipients with the HLA-DQ heterodimer 
consisting of DQA1*05:01 and DQB1*03:01 were also unlikely to produce nAb after 
vaccination [17]. Future vaccine trials may need to consider HLA class II genotyping as 
another useful tool for deciphering correlates of immune protection, as supported by 
preclinical findings from an SIV-macaque model [18]. Of note, HLA class II alleles 
implicated by the RV144 trial bear no similarity to those (e.g. DRB1*01, *03, *07 and *15) 
reported earlier for several routinely applied vaccines, suggesting that nAb responses may 
differ by vaccine constructs and/or dosing regimens.
Unlike potent anti-HIV nAb that acts relatively late in the course of HIV infection, CTLs 
and NK cells presumably act early. As such, HLA class I and KIR gene variants with distinct 
functional properties can be analyzed against early phenotypes. This hypothesis has been 
tested in recent HIV seroconverters from sub-Saharan African countries [19]. In the acute-
phase of HIV infection (duration of infection <3 months), the majority of seroconverters 
with effective control of viremia had HLA-B*44 and B* 57 – 2 favorable HLA variants in 
the cohort [19]. These allelic products are known to target multiple conserved HIV epitopes, 
but their functional advantages may also further reflect intrinsic differences in protein 
expression [20]. One study has also called for close attention to HLAC expression, as certain 
alleles (e.g. C*06:02) may be functionally advantageous through avoidance of down-
regulation by microRNAs [21]. HLA-KIR interactions can provide another dimension for 
gauging the relevance of HLA function to HIV control, as at least 22 nonsynonymous 
mutations in the HIV genome are apparently attributable to several KIR genes (especially 
KIR2DL2) [22]. A clear picture about these multifactorial and multidimensional pathways 
may emerge soon to allow a fine-mapping of HIV mutations induced by CTL, nAb, NK, and 
other related effectors mediated by HLA and KIR gene products. However, it will require 
much more painstaking effort to determine the selection of these mutations relative to 
individual immune pressure, their patterns of reversion in the absence of immune pressure, 
and the replication capacity of mutated viruses. Further study will be necessary to 
understand the interplay between human immunogenetics and HIV in order to implement 
treatment and prevention methods with maximum efficacy.
Detection of Antiretroviral Drug Resistance
A complication in HIV clinical care stemming from the high mutation rate and genetic 
diversity of HIV is the emergence and persistence of mutations that confer resistance to 
drugs used in antiretroviral therapy (ART). Because primary or transmitted drug resistance 
mutations are associated with poorer treatment outcomes, a Department of Health and 
Human Services panel recommended that all persons newly diagnosed with HIV infection 
receive an HIV genotype prior to initiating therapy [23]. The conventional method for virus 
genotyping is Sanger sequencing; however, the sensitivity of this technology is limited in 
that it is unlikely to detect in individuals a variant present at a frequency of less than 20–
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30% of the quasispecies [24]. This limitation can lead to underestimating the burden of 
resistance in drug-naïve individuals, particularly for persons diagnosed long after becoming 
infected when transmitted resistant viruses may have become supplanted by more fit 
wildtype virus. Resistance can also be underestimated in ART-experienced individuals who 
may have low-expressing archived variants selected by prior treatment regimens [25]. The 
development of sensitive genotyping tools that allow for finer resolution of quasispecies 
subpopulations has uncovered hidden drug-resistant variants that are undetected by 
conventional sequencing. Some of the more common molecular methods used for resistance 
mutation detection include allele-specific or mutation-specific real-time PCR [26, 27], 
parallel allele-specific sequencing [28], ultra- deep (pyro) sequencing [29], and single-
genome sequencing [30], each with inherent technical complexities and resource 
requirements.
In a study of newly diagnosed ART-naïve individuals from North America, who had either 
wildtype HIV infections or who had at least one resistance-associated mutation as 
determined by conventional genotyping, allele (mutation)-specific PCR testing found 
previously undetected low-frequency transmitted resistance mutations in both groups [31]. 
The detection of minority resistance mutations in 17% of the conventionally genotyped 
wildtype virus samples and the identification of additional mutations in 10% of those with 
evidence of other resistance mutations suggested that bulk genotyping missed at least 40% 
of transmitted mutations in this population. Furthermore, the finding that some individuals 
had evidence of HIV resistant variants of distinct genotypes implied that it was possible for 
infections to involve more than one variant with the potential to impact treatment outcomes. 
Sensitive genotyping for surveillance, however, may not offer substantially more information 
than conventional genotyping in geographic regions with less-extensive treatment histories 
and lower prevalences of transmitted resistance.
In a case-control study also by Johnson et al. [31], mutation-specific PCR testing identified 
that 7/95 (7%) persons who experienced virological failure on first-line efavirenz-based 
ART had low-frequency drug resistance mutations at baseline; whereas, low-frequency 
resistance was found in only 2/221 (0.9%) treatment successes (p = 0.0038). A study by 
Goodman et al. [32], using allele-specific PCR at a mutation lower cut-off of 0.5%, found 
that minority-level detection of K103N, a non-nucleoside reverse transcriptase inhibitor 
(NNRTI) mutation, when present at ≥2,000 copies/ml was associated with a significant ~47-
fold higher risk of virological failure in first-line NNRTI-based ART [32]. This suggested 
that higher resistant variant loads within low-level populations were more strongly 
associated with treatment failure. Simen et al. [33] employed ultra-deep sequencing with a 
mutation detection lower limit of 1% to assess resistance in drug-naïve patients starting ART 
within the Flexible Initial Retrovirus Suppressive Therapies (FIRST) study of 3 initial 
regimens. Twice as many participants were identified to have resistance mutations with 
ultra-deep sequencing than was detected by standard sequencing, 28% versus 14%, 
respectively (p < 0.001). The presence of NNRTI resistance detected only by ultra-deep 
sequencing was significantly associated with virologic failure (HR 2.50; 95% CI, 1.17–
5.36). Taken together, these findings strongly support that, at least for NNRTI combination 
therapies with dual NRTIs, NNRTI-resistant variants may retain their impact even if present 
at a low frequency within the quasispecies.
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Low-frequency mutations, however, do not universally impact ART. Lataillade et al. [34] 
reported that in persons virologically failing on ritonavir-boosted protease inhibitor (PI/r) 
regimens, ultra-deep sequencing identified major protease inhibitor mutations at low levels 
only sporadically, and those variants remained susceptible to the boosted PI. Moreover, 
Codoñer et al. [35] retrospectively assessed the value of sensitive testing on predicting the 
success of salvage therapy for HIV-infected persons with heavy treatment histories and who 
have experienced virologic failure with deep salvage therapy. Here, again the additional few 
PI resistance mutations identified by deep sequencing prior to salvage therapy were 
inconsistently predictive of PI susceptibility.
Finally, another potential use for sensitive genotyping was revealed in the deep sequencing 
of the env V3 region by Swenson et al. [36] from participants who received either the R5-
specific entry inhibitor maraviroc or the NNRTI efavirenz in the MERIT trial. In this 
analysis, identification of low-level non-R5-tropic viruses at study entry were associated 
with poorer maraviroc treatment outcomes than those in the efavirenz arm. Limiting 
maraviroc to those with only R5-tropic virus would have resulted in maraviroc having a 
noninferior response to efavirenz. Therefore, because minority-level resistance class and 
design of antiretroviral regimen can impact treatment success, the benefit of sensitive 
genotyping in clinical management requires further exploration.
Conclusion
The advent of new sequencing and bioinformatics tools are beginning to benefit the 
development of improved methods for treating and preventing HIV infection. Despite the 
complicated genetic variability of HIV, sequencing and bioinformatics tools provide promise 
for identification of future viral targets of HIV prevention methods. Comprehensive studies 
of immunogenetics and viral sequences are beginning to understand the complicated 
interplay between virus and host, whereby specific alleles are associated with faster or 
slower disease progression. Increasingly sensitive ARV drug resistance testing methods have 
made it possible to detect minority drug resistance mutations which may impact the success 
of clinical patient management. In summary, data generated by studies of viral genetics and 
human immunogenetics provide valuable information to guide development of new 
strategies to improve HIV treatment and prevention.
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